First Trial Underway, CytomX Gets $200M More In Expanded Bristol Pact

From Xconomy VC, Deals, & Startups
March 20, 2017 - 8:22am
It’s tough to stand out in the cancer immunotherapy crowd, where a slew of companies are testing a variety of drug combinations and new methods to help boost responses to existing treatments. But CytomX Therapeutics has clearly gotten the attention of one of the field’s major players, Bristol-Myers Squibb, which has just re-upped and expanded […]

Continue reading this article »